Sensei Biotherapeutics, Inc.

SNSE

US81728A1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:01 2024-04-29 EDT			5-day change	1st Jan Change
1.02 ^USD	0.00%		+9.57%	+47.40%

04-24	Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting	CI
04-04	Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of Vista Within the Tumor Microenvironment	CI

Sensei Biotherapeutics, Inc.(NasdaqGM:SNSE) added to Russell Microcap Index

March 19, 2021 at 12:00 am

Latest news about Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting	04-24	CI
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of Vista Within the Tumor Microenvironment	04-04	CI
Sensei Biotherapeutics, Inc. Announces Resignation of Erin Colgan as Chief Financial Officer, Effective April 10, 2024	04-02	CI
North American Morning Briefing : Stocks Set for -2-	03-28	DJ
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Sensei Biotherapeutics, Inc. Announces Management Changes	02-08	CI
HC Wainwright Initiates Sensei Biotherapeutics With Buy Rating, Price Target is $4	12-04	MT
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	11-07	CI
Newtyn Partners, LP and Newtyn TE Partners, LP, managed by Newtyn Management, LLC cancelled the acquisition of remaining 93.48% stake in Sensei Biotherapeutics, Inc..	11-05	CI
Newtyn Partners, LP and Newtyn TE Partners, LP, managed by Newtyn Management, LLC made a proposal to acquire remaining 93.48% stake in Sensei Biotherapeutics, Inc. for $25 million.	11-02	CI
Sensei Biotherapeutics, Inc. Appoints Stephanie Krebs, Ms, Mba, as Chief Business Officer	11-01	CI
Sensei Biotherapeutics, Inc. to Present Initial Clinical Data from Dose Escalation Trial of SNS 101 At 2023 SITC Annual Meeting	23-10-25	CI
Sensei Biotherapeutics Doses First Patient in Combination Study of SNS-101 With Libtayo	23-09-27	MT
Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo	23-09-27	CI
Sensei Biotherapeutics Says New Data Reinforce SNS-101 Pharmacokinetic, Safety Profile	23-09-21	MT
Sensei Biotherapeutics, Inc. Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action	23-09-21	CI
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023	23-08-03	CI
Sensei Biotherapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101	23-06-01	CI
Apeiron Investment Withdraws its Notice of Intent to Nominate Director at Sensei Biotherapeutics	23-05-23	CI
Sensei Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Sector Update: Health Care Stocks Weaker Late Afternoon	23-04-20	MT
Sector Update: Health Care Stocks Dropping Thursday Afternoon	23-04-20	MT
Sensei Biotherapeutics Says US FDA Approves Investigational New Drug Application for Cancer Drug Candidate SNS-101	23-04-20	MT
Sensei Biotherapeutics, Inc. Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active Vista-Blocking Antibody	23-04-20	CI
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI

Chart Sensei Biotherapeutics, Inc.

Duration

Period

More charts

Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Its lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation checkpoint selectively within the low pH tumor microenvironment. It is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

SENSEI BIOTHERAPEUTICS : Mixed Q3; but cash cushion remains intact

November 10, 2022 at 06:59 am

More Strategies

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.02 USD

Average target price

4.667 USD

Spread / Average Target

+357.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SENSEI BIOTHERAPEUTICS, INC.	+47.40%	25.57M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B
ARGENX SE	+1.63%	22.18B
BIONTECH SE	-16.67%	21.2B
GENMAB A/S	-8.63%	18.31B
WUXI APPTEC CO., LTD.	-38.74%	17.38B
BEIGENE, LTD.	-13.21%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs